Where Regeneron Pharmaceuticals Stands With Analysts

Loading...
Loading...

Within the last quarter, Regeneron Pharmaceuticals REGN has observed the following analyst ratings:

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 3 6 4 0 0
Last 30D 0 0 1 0 0
1M Ago 2 2 0 0 0
2M Ago 1 4 3 0 0
3M Ago 0 0 0 0 0

These 13 analysts have an average price target of $841.62 versus the current price of Regeneron Pharmaceuticals at $745.2, implying upside.

Below is a summary of how these 13 analysts rated Regeneron Pharmaceuticals over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

This current average has increased by 5.43% from the previous average price target of $798.30.

Stay up to date on Regeneron Pharmaceuticals analyst ratings.

How Are Analyst Ratings Determined?

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Loading...
Loading...
date
▲▼
ticker
▲▼
name
▲▼
Price Target
▲▼
Upside/Downside
▲▼
Recommendation
▲▼
Firm
▲▼
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...